← Back
Data updated: Mar 10, 2026
SEAGEN
OncologyGastroenterologyImmunology
SEAGEN is a biotechnology company focused on Oncology, Gastroenterology, Immunology. Key products include TUKYSA.
2020
Since
2
Drugs
-
Trials
2
Approved (2yr)
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 87%
2 drugs Phase 3: 8 Phase 2: 22 Phase 1: 28
Gastroenterology 11%
0 drugs Phase 2: 4 Phase 1: 6
Immunology 2%
0 drugs Phase 2: 1 Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology, Immunology